The outbreak of SARS-CoV-2 started in Hubei province of China in December 2019 and rapidly spread all over the world. It has infected more than 7 million people worldwide and has pushed half of the world in a state of lockdown. There is an urgent unmet need of interventions both for prevention and treatment of this disease and more than 500 clinical trials are ongoing in this regard. At present, no study with robust methodology have clearly demonstrated benefits of hydroxychloroquine for treatment, preexposure prophylaxis in healthcare workers or post exposure prophylaxis in COrona VIrus Disease-2019. Remdesivir has been shown to have modest benefits in moderate to severe disease, if administered early. Given the rapid pace of clinical information and discoveries, it is important for clinicians to be up to date with the latest, evidence-based treatment options available for this novel disease. Keeping up with this current pace of information, we review the clinical studies of different therapeutic options available to treat SARS-CoV-2.
Keywords: ARDS, Acute Respiratory Distress Syndrome; COVID-19; COVID-19 treatment; COVID-19, COrona VIrus Disease - 2019; CQ, Chloroquine; HCQ, Hydroxychloroquine; IL-6, Interleukin-6; INF, Interferon; LPV/TRV, Lopinavir/ritonavir; SARS-CoV-2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; TCZ, Tocilizumab; WHO, World Health Organization; coronavirus disease; novel coronavirus.
© 2020 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.